Takeda prices US$500 million senior note offering

July 11, 2017

Osaka, Japan, July 12, 2017 – Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it has successfully priced its US$500 million senior note offering, as outlined below. 

1. Issue Amount

US$500 million

2. Coupon

2.45% per annum

3. Payment of Coupon

To be paid semi-annually in arrears on January 18 and July 18 of
each year, beginning on January 18, 2018

4. Issue Price

99.915% of the principal amount

5. Term

4.5 years

6. Maturity Date

January 18, 2022

7. Issue Date

July 18, 2017

8. Use of proceeds

To repay short-term interest-bearing debt which resulted from the acquisition of ARIAD Pharmaceuticals, Inc., headquartered in Cambridge MA, U.S. on February 16, 2017

9. Method of Offering

Private offering in foreign markets including the U.S., Europe and Asia (The notes will not be offered or sold within the U.S. or to U.S. persons, except to “qualified institutional buyers” in reliance on the exemption from registration provided by Rule 144A under the U.S. Securities Act of 1933, as amended)

10. Ratings

A1 (Moody’s), A- (S&P)

 


Media Contact:
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095

Note: This document is prepared for the purpose of public disclosure of determination of the terms of the securities, and does not constitute an offer to sell or a solicitation of an offer to buy any securities in or outside of the U.S. or Japan. The securities set forth above have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the U.S. absent registration or an applicable exemption from the registration requirements of the Securities Act.